Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy in Adults and Pediatric Patients*
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy at the European Society of Cardiology Congress 2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Market One Minute Feature on BNN Bloomberg: Omega Pacific Resources Drills to Expand Gold Discovery in BC's Toodoggone
QIMC Engages Global Seismic Processing Leader Earth Signal to Advance Nova Scotia Hydrogen and Helium Multi-Gas Pilot Production Pathway
